News

The acquisition is centered on development of the UK firm’s Phase II clinical candidate CNV1014802, which has showed clinical activity in proof of concept trials for trigeminal neuralgia

Both the trials, which met their primary efficacy endpoints, compared the reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks with alirocumab versus placebo in these

Currently, Syndax is developing entinostat, a Class I selective histone deacetylase (HDAC) inhibitor, in the US and Europe in combination with hormone therapy for advanced breast cancer and

Patent No. 8,916,588 "Methods of Treatment for Attention Deficit Hyperactivity Disorder" and Patent No. 8,927,010 "Compositions for Treatment of Attention Deficit Hyperactivity Disorder" are owned by Highland’s wholly

The vaccines work of Valera builds on a body of preclinical research at Moderna showing the ability of modified mRNA to express viral antigens in vivo and to

The clinical results reported are from 9 patients, 6 of which carried the worst KS prognosis. Also, 4 of the 9 patients had received from 1 to 8

Danshensu Yibingzhi (IDHP) was developed by Professor Xiaohui Zheng and his research team after 14 years of concerted research effort and was recently approved by the Education Department

The results from the EXPEDITION (including FLIGHT 1, 2 and 3 studies) and GEM clinical trial programs met their primary and secondary endpoints. COPD symptoms can negatively impact

RYTARY is an extended-release oral capsule formulation of carbidopa-levodopa. It is not indicated for use in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors. The drug contains immediate